Outlook Therapeutics (Nasdaq:OTLK) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

OTLK 주식 개요

임상 단계의 바이오 제약 회사로서 다양한 안과 적응증을 위한 단일 클론 항체 개발 및 상용화에 주력하고 있는 Outlook Therapeutics, Inc.

OTLK 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	5/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

수익은 매년 67.53% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

마이너스 주주 지분

수익이 1백만 달러 미만인 경우 ( $0 )

Outlook Therapeutics, Inc. 경쟁사

INmune Bio

NasdaqCM:INMB

US$174.5m

Fennec Pharmaceuticals

NasdaqCM:FENC

US$166.9m

Acrivon Therapeutics

NasdaqGM:ACRV

US$179.1m

Shattuck Labs

NasdaqGS:STTK

US$183.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Outlook Therapeutics
과거 주가
현재 주가	US$7.41
52주 최고치	US$37.00
52주 최저치	US$4.00
베타	0.65
11개월 변경	4.81%
3개월 변경 사항	-23.61%
1년 변경 사항	-78.33%
33년 변화	-84.43%
5년 변화	-83.89%
IPO 이후 변화	-98.92%

최근 뉴스 및 업데이트

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

주주 수익률

	OTLK	US Biotechs	US 마켓
7D	-0.3%	-1.9%	0.5%
1Y	-78.3%	10.4%	20.5%

수익률 대 산업: OTLK 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: OTLK 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is OTLK's price volatile compared to industry and market?
OTLK volatility
OTLK Average Weekly Movement	7.7%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.8%

안정적인 주가: OTLK 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: OTLK 의 주간 변동성은 지난 1년 동안 21% 에서 9% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2010	24	Russ Trenary	www.outlooktherapeutics.com

임상 단계의 바이오 제약 회사로서 다양한 안과 적응증에 대한 단일 클론 항체를 개발하고 상용화하는 데 주력하고 있는 아웃룩 테라퓨틱스(Outlook Therapeutics, Inc.)가 있습니다. 주요 제품 후보로는 습성 연령 관련 황반변성 및 기타 망막 질환 치료를 위한 임상 3상 시험 중인 베바시주맙의 안과용 제형 제품 후보인 ONS-5010이 있습니다. 아웃룩 테라퓨틱스는 바이오렉시스(BioLexis Pte.

Outlook Therapeutics, Inc. 기본 사항 요약

Outlook Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
OTLK 기본 통계
시가총액	US$172.73m
수익(TTM)	-US$159.13m
수익(TTM)	n/a

0.0x

P/S 비율

-1.1x

P/E 비율

OTLK 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
OTLK 손익 계산서(TTM)
수익	US$0
수익 비용	US$26.45m
총 이익	-US$26.45m
기타 비용	US$132.68m
수익	-US$159.13m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-6.80
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	-33.3%

OTLK 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

OTLK 주식 개요

보상

위험 분석

Outlook Therapeutics, Inc. 경쟁사

NasdaqCM:INMB

US$174.5m

NasdaqCM:FENC

US$166.9m

NasdaqGM:ACRV

US$179.1m

NasdaqGS:STTK

US$183.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Recent updates

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58